Janney Montgomery Scott LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 94 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.0%.

Quarter-by-quarter ownership
Janney Montgomery Scott LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$4
-90.2%
20,0000.0%0.00%
Q2 2023$41
+24.2%
20,0000.0%0.00%
Q4 2022$33
-100.0%
20,0000.0%0.00%
Q3 2022$88,000
-7.4%
20,000
-4.3%
0.00%
Q4 2020$95,000
-74.3%
20,890
-4.6%
0.00%
-100.0%
Q3 2020$370,000
+203.3%
21,890
+101.0%
0.00%
+100.0%
Q2 2020$122,000
+154.2%
10,890
+4.7%
0.00%
Q1 2020$48,00010,4000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2020
NameSharesValueWeighting ↓
Weaver Consulting Group 130,000$437,0000.21%
Ikarian Capital, LLC 304,161$1,022,0000.13%
ABNER HERRMAN & BROCK LLC 265,000$890,0000.12%
S.C. Financial Services, Inc. 15,285$51,0000.06%
JMAC ENTERPRISES LLC 45,430$153,0000.04%
CFO4Life Group, LLC 12,000$40,0000.01%
OSAIC HOLDINGS, INC. 10,839$1,329,0000.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$10,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 29,186$98,0000.00%
RAYMOND JAMES & ASSOCIATES 190,403$640,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders